SG11202012674PA - Heterocyclic and heteroaryl compounds for treating huntington's disease - Google Patents

Heterocyclic and heteroaryl compounds for treating huntington's disease

Info

Publication number
SG11202012674PA
SG11202012674PA SG11202012674PA SG11202012674PA SG11202012674PA SG 11202012674P A SG11202012674P A SG 11202012674PA SG 11202012674P A SG11202012674P A SG 11202012674PA SG 11202012674P A SG11202012674P A SG 11202012674PA SG 11202012674P A SG11202012674P A SG 11202012674PA
Authority
SG
Singapore
Prior art keywords
heterocyclic
disease
heteroaryl compounds
treating huntington
huntington
Prior art date
Application number
SG11202012674PA
Inventor
Nadiya Sydorenko
Md Rauful Alam
Michael A Arnold
Suresh Babu
Anuradha Bhattacharyya
Guangming Chen
Aleksey I Gerasyuto
Gary Mitchell Karp
Andrew J Kassick
Anthony R Mazzotti
Young-Choon Moon
Jana Narasimhan
Jigar Patel
Anthony Turpoff
Matthew G Woll
Wuming Yan
Nanjing Zhang
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of SG11202012674PA publication Critical patent/SG11202012674PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11202012674PA 2018-06-27 2019-06-25 Heterocyclic and heteroaryl compounds for treating huntington's disease SG11202012674PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690653P 2018-06-27 2018-06-27
PCT/US2019/038889 WO2020005873A1 (en) 2018-06-27 2019-06-25 Heterocyclic and heteroaryl compounds for treating huntington's disease

Publications (1)

Publication Number Publication Date
SG11202012674PA true SG11202012674PA (en) 2021-01-28

Family

ID=67180896

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012674PA SG11202012674PA (en) 2018-06-27 2019-06-25 Heterocyclic and heteroaryl compounds for treating huntington's disease

Country Status (17)

Country Link
US (1) US11858941B2 (en)
EP (1) EP3814357B1 (en)
JP (1) JP7421507B2 (en)
KR (1) KR20210042265A (en)
CN (1) CN112654625A (en)
AR (1) AR119651A1 (en)
AU (2) AU2019294478B2 (en)
BR (1) BR112020026545A2 (en)
CA (1) CA3103976A1 (en)
CL (3) CL2020003378A1 (en)
CO (1) CO2020016285A2 (en)
EA (1) EA202092896A1 (en)
IL (1) IL279688A (en)
MX (1) MX2020014098A (en)
PE (1) PE20211378A1 (en)
SG (1) SG11202012674PA (en)
WO (1) WO2020005873A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697709A (en) 2015-12-10 2018-10-23 Ptc医疗公司 Method for treating Huntington disease
WO2018226622A1 (en) 2017-06-05 2018-12-13 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
EP3644996B1 (en) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Methods for treating huntington's disease
SG11202000980QA (en) 2017-08-04 2020-02-27 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
CN112020500A (en) 2017-12-22 2020-12-01 拉文纳制药公司 Aminopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase
CN112135815A (en) 2018-03-27 2020-12-25 Ptc医疗公司 Compounds for the treatment of huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
CA3103976A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
JP2022521467A (en) 2019-02-05 2022-04-08 スカイホーク・セラピューティクス・インコーポレーテッド Methods and compositions for regulating splicing
CN113677344A (en) 2019-02-06 2021-11-19 斯基霍克疗法公司 Methods and compositions for modulating splicing
CN113840602A (en) * 2019-03-15 2021-12-24 斯基霍克疗法公司 Compositions and methods for correcting aberrant splicing
WO2020231977A1 (en) * 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
TW202131920A (en) 2019-11-01 2021-09-01 瑞士商諾華公司 The use of a splicing modulator for a treatment slowing progression of huntington’s disease
CA3182912A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
TW202216725A (en) 2020-07-02 2022-05-01 美商雷密克斯醫療公司 Compounds and methods for modulating splicing
BR112022027107A2 (en) 2020-07-02 2023-03-14 Remix Therapeutics Inc 2-(INDAZOL-5-IL)-6-(PIPERIDIN-4-IL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR NUCLEIC ACID SPLICING AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022060951A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
WO2022060943A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
WO2022060944A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
US20220162610A1 (en) * 2020-11-12 2022-05-26 Ptc Therapeutics, Inc. Novel rna transcript
WO2022104058A1 (en) 2020-11-13 2022-05-19 Ptc Therapeutics Inc. Tablet for use in treating huntington's disease and method of making the same
CN116997555A (en) * 2021-03-17 2023-11-03 豪夫迈·罗氏有限公司 Novel thienopyrimidinone derivatives
TW202304446A (en) 2021-03-29 2023-02-01 瑞士商諾華公司 The use of a splicing modulator for a treatment slowing progression of huntington’s disease
EP4377317A1 (en) 2021-07-30 2024-06-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2023081857A1 (en) * 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Condensed pyridazine amine derivatives treating sca3
WO2023220134A1 (en) * 2022-05-10 2023-11-16 Foghorn Therapeutics Inc. Pyrazine derivatives and uses thereof
WO2023244996A2 (en) * 2022-06-15 2023-12-21 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (en) 1963-04-04 1900-01-01
US3558618A (en) 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
GB1383409A (en) 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US4122274A (en) 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
US4342870A (en) 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
JPS56150091A (en) 1980-03-28 1981-11-20 Janssen Pharmaceutica Nv 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
FR2567518B1 (en) 1984-07-11 1987-11-13 Sanofi Sa NOVEL NITROGEN HETEROCYCLIC CORE COMPOUNDS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THE SAME
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US5599816A (en) 1990-05-02 1997-02-04 Abbott Laboratories Quinolizinone type compounds
AU4231293A (en) 1992-05-13 1993-12-13 E.I. Du Pont De Nemours And Company Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides
ATE368107T1 (en) 1993-05-11 2007-08-15 Univ North Carolina ANTISENSE OLIGONUCLEOTIDES THAT PREVENT ANOMAL SPLICING AND THEIR USE
JPH11510478A (en) 1995-06-06 1999-09-14 アボツト・ラボラトリーズ Quinolidinone type compounds
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
CA2269561C (en) 1998-04-22 2007-06-05 Dainippon Ink And Chemicals, Inc. Naphthalene derivative and liquid crystal composition comprising the same
EP1115724A1 (en) 1998-09-21 2001-07-18 Shire Biochem Inc. Quinolizinones as integrin inhibitors
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
EP1227084B1 (en) 1999-10-28 2005-12-14 Trine Pharmaceuticals, Inc. Drug discharge pump inhibitors
CA2398163C (en) 2000-01-24 2011-02-22 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
WO2002038738A2 (en) 2000-11-09 2002-05-16 Cold Spring Harbor Laboratory Chimeric molecules to modulate gene expression
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
US6653300B2 (en) 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
WO2002087589A1 (en) 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Medicine for inhibiting drug elimination pump
WO2003049739A1 (en) 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
ATE548354T1 (en) 2002-07-24 2012-03-15 Ptc Therapeutics Inc UREIDO-SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND TREATMENT OF DISEASES
WO2004019002A2 (en) 2002-08-23 2004-03-04 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent glycosides and methods for their use
DE60311853T2 (en) 2002-09-30 2007-06-21 Neurosearch A/S NEW 1,4-DIAZABICYCLOALKAN DERIVATIVES, THEIR PREPARATION AND USE
US20070078144A1 (en) 2003-01-29 2007-04-05 Stockwell Brent R Agents for treating neurodegenerative diseases
CN1809563A (en) 2003-06-20 2006-07-26 希龙公司 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
GB0315494D0 (en) 2003-07-02 2003-08-06 Biofocus Plc Compounds which bind to the active site of protein kinase enzymes
TW200517381A (en) 2003-08-01 2005-06-01 Genelabs Tech Inc Bicyclic heteroaryl derivatives
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050137203A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7309699B2 (en) 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
JP5384793B2 (en) 2003-12-24 2014-01-08 バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド Polycyclic drugs for the treatment of respiratory syncytial virus infection
SE0400184D0 (en) 2004-01-30 2004-01-30 Fyrkloevern Scandinavia Ab New therapeutic use
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
US20070191374A1 (en) 2004-04-08 2007-08-16 Neurogen Coroperation Substituted cinnolin-4-ylamines
ATE373659T1 (en) 2004-05-04 2007-10-15 Warner Lambert Co PYRROLYL SUBSTITUTED PYRIDO(2,3-D)PYRIMIDINE-7-ONE AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS
EP1846397A1 (en) 2005-01-21 2007-10-24 Janssen Pharmaceutica N.V. Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors
US7879992B2 (en) 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP2006219453A (en) 2005-02-14 2006-08-24 Tokyo Univ Of Pharmacy & Life Science Metal-discrimination-type two-color fluorescent molecule containing quinoline ring as parent nucleus
US7563601B1 (en) 2005-06-01 2009-07-21 City Of Hope Artificial riboswitch for controlling pre-mRNA splicing
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
KR101286569B1 (en) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 Novel medicaments
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
WO2007047913A2 (en) 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression
JP2009515523A (en) 2005-11-10 2009-04-16 サンタリス ファーマ アー／エス Splice-switching oligomers for TNF superfamily receptors and use of the oligomers in disease treatment
WO2007065892A1 (en) 2005-12-06 2007-06-14 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
JP2009520700A (en) 2005-12-21 2009-05-28 ペインセプター ファーマ コーポレーション Compositions and methods for modulating gated ion channels
EP2428227B1 (en) 2006-01-26 2016-06-22 Ionis Pharmaceuticals, Inc. Compositions and their uses directed to Huntingtin
JP5213723B2 (en) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド Oligomer compounds and compositions for use in modulating microRNA
AR059339A1 (en) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd CUMARINE DERIVATIVES FOR PROLIFERATIVE DISORDERS OF CELLS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC AGENT CONTAINING THEM
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2007133756A2 (en) * 2006-05-15 2007-11-22 Neurogen Corporation Crf1 receptor ligands comprising heteroaryl fused bicycles
JP2009537599A (en) 2006-05-23 2009-10-29 ノイロサーチ アクティーゼルスカブ Novel 8,10-diaza-bicyclo [4.3.1] decane derivatives and their medical use
CA2658462C (en) 2006-07-20 2011-09-27 Amgen Inc. Substituted pyridone compounds and methods of use
US8337941B2 (en) 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
PT2066653E (en) 2006-08-03 2012-10-22 Rottapharm Spa 6-1h-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
JP2010507619A (en) 2006-10-25 2010-03-11 ノイロサーチ アクティーゼルスカブ Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
AU2007336703B9 (en) 2006-12-22 2014-03-27 Avexa Limited Bicyclic pyrimidinones and uses thereof
WO2008083226A2 (en) 2006-12-28 2008-07-10 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
FR2914188B1 (en) 2007-03-28 2012-06-22 Trophos NEW CHOLEST-4-EN-3-ONE OXIME COMPOSITION
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EP2215074B1 (en) 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
PL2193133T3 (en) 2007-09-27 2016-01-29 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazolothiadiazoles for use as protein kinase inhibitors
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009126635A1 (en) 2008-04-09 2009-10-15 Abbott Laboratories 2-amino-benzothiazole derivates useful as inhibitors of rock kinases
WO2009131958A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
AU2008357946B2 (en) 2008-06-20 2013-06-20 Rottapharm Biotech S.R.L. 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
WO2010000032A1 (en) 2008-07-02 2010-01-07 Avexa Limited Compounds having antiviral properties
US8986935B2 (en) 2008-08-13 2015-03-24 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010024903A1 (en) 2008-08-29 2010-03-04 Yangbo Feng BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS
US20110224187A1 (en) 2008-10-16 2011-09-15 Anandan Palani Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2379564A1 (en) 2008-12-19 2011-10-26 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
BRPI1008020A2 (en) 2009-02-11 2016-03-15 Sunovion Pharmaceuticals Inc histamine h3 antagonists and inverse agonists and methods of using them
FR2945289A1 (en) 2009-05-11 2010-11-12 Sanofi Aventis 2-CYCLOAMINO-5- (PYRIDIN-4-YL) IMIDAZO-2,1-B1 DERIVATIVES 1,3,4! THIADIAZOLE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
AU2010262643B2 (en) 2009-06-19 2015-02-19 Abbvie Inc. Diazahomoadamantane derivatives and methods of use thereof
BR112012005448B1 (en) 2009-09-11 2021-09-14 Ionis Pharmaceuticals, Inc SIMPLE TAPE MODIFIED OLIGONUCLEOTIDE AIMED AT A NUCLEIC ACID THAT ENCODES HUNTINGTIN AND CAPABLES TO INHIBIT HUNTINGTIN EXPRESSION, COMPOSITION INCLUDING THE SAME AND ITS USE TO PREVENT, TREAT, IMPROVE, AND REDUCE THE HAXATING RATE
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
WO2011057204A2 (en) 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
WO2011062853A1 (en) 2009-11-20 2011-05-26 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
EP2523956A1 (en) 2010-01-13 2012-11-21 Institut Pasteur Korea Anti - infective pyrido (1,2 -a) pyrimidines
JP2013518603A (en) 2010-02-08 2013-05-23 アイシス ファーマシューティカルズ， インコーポレーテッド Methods and compositions useful for the treatment of diseases or conditions associated with repeated stretch
EP3208347B1 (en) 2010-02-08 2019-08-14 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
US8957040B2 (en) 2010-02-08 2015-02-17 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
CA2800509A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP3633038A3 (en) 2010-07-19 2020-07-29 Ionis Pharmaceuticals, Inc. Modulation of dystrophia myotonica-protein kinase (dmpk) expression
WO2012019106A2 (en) 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
CN102617548A (en) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 Bicycloheteroaryl compounds as GPR Receptor stimulant, compositions and application thereof
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
EP3067421B1 (en) 2011-02-08 2018-10-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US9447075B2 (en) 2011-08-02 2016-09-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as EAAT2 activators
EP4269584A3 (en) 2011-08-11 2024-03-27 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
EP2560008B1 (en) 2011-08-18 2016-11-30 Korea Institute of Science and Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
EP2751269B1 (en) 2011-08-29 2016-03-23 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
WO2013059606A1 (en) 2011-10-21 2013-04-25 Tufts Medical Center, Inc. Compounds and methods for the treatment of muscular disease, and related screening methods
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
MX2014006409A (en) 2011-11-28 2014-07-30 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
KR102057351B1 (en) 2011-12-30 2019-12-18 피티씨 테라퓨틱스, 인크. Compounds for treating spinal muscular atrophy
CN104203239B (en) 2012-01-26 2017-09-08 Ptc医疗公司 Compound for treating Duchenne-Arandisease
KR102137087B1 (en) 2012-02-10 2020-07-24 피티씨 테라퓨틱스, 인크. Compounds for treating spinal muscular atrophy
CN104302181B (en) 2012-03-01 2017-09-15 Ptc医疗公司 Compound for treating Duchenne-Arandisease
BR112014023483B1 (en) 2012-03-23 2022-05-10 Ptc Therapeutics, Inc Compound and its use, pharmaceutical composition and its use
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
EP2872493B1 (en) 2012-07-13 2018-11-14 Indiana University Research and Technology Corporation 5,6,7-trimethoxy 4-phenyl quinolin-2-one derivatives for treatment of spinal muscular atrophy
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
WO2014059341A2 (en) 2012-10-12 2014-04-17 Isis Pharmaceuticals, Inc. Antisense compounds and uses thereof
EP3459549B1 (en) 2012-10-12 2022-04-06 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
PL2911671T3 (en) 2012-10-25 2018-11-30 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9227976B2 (en) * 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP6255711B2 (en) 2012-11-01 2018-01-10 株式会社リコー Electrochromic compound, electrochromic composition, and display element
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
EP2951304B1 (en) 2013-02-04 2020-07-08 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
CN105026398B (en) 2013-03-05 2018-05-18 默克专利股份公司 For treating the triazol of diseases such as cancer [4,5-d] pyrimidine derivatives
CA2910508A1 (en) 2013-05-14 2014-11-20 Song Feng Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
EP3013345B1 (en) 2013-06-25 2017-11-22 F. Hoffmann-La Roche AG Compounds for treating spinal muscular atrophy
MX2020011652A (en) 2013-07-31 2022-09-27 Novartis Ag 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions.
RU2016109324A (en) 2013-08-19 2017-09-26 Ф. Хоффманн-Ля Рош Аг SCREENING METHOD
WO2015095446A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2015105657A1 (en) 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
US9624170B2 (en) * 2013-12-26 2017-04-18 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
AR099134A1 (en) 2014-01-24 2016-06-29 Hoffmann La Roche PROCEDURE FOR THE PREPARATION OF N - [(3-AMINOOXETAN-3-IL) METHYL] -2- (1,1-DIOXO-3,5-DIHIDRO-1,4-BENZOTIAZEPÍN-4-IL) -6-METIL- QUINAZOLÍN-4-AMINA
CA2940621C (en) 2014-03-14 2022-03-15 Raqualia Pharma Inc. Azaspiro derivatives as trpm8 antagonists
EP3119761B1 (en) 2014-03-19 2023-06-07 Amydis Diagnostics, Inc. Amyloid targeting agents and methods of using the same
MX371050B (en) 2014-05-15 2020-01-14 Hoffmann La Roche Compounds for treating spinal muscular atrophy.
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
WO2015195811A2 (en) 2014-06-17 2015-12-23 Novozymes A/S Biological phosphorus removal from wastewater
CA2952895C (en) 2014-06-25 2023-09-26 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy
US20180282347A1 (en) 2014-12-02 2018-10-04 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pest control agents
EP3540063A1 (en) 2014-12-24 2019-09-18 uniQure IP B.V. Rnai induced huntingtin gene suppression
CA3199430A1 (en) 2015-01-16 2016-07-21 The General Hospital Corporation Compounds for improving mrna splicing
JP6884102B2 (en) 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Compounds for the treatment of cancer
GB201502567D0 (en) 2015-02-16 2015-04-01 Sentinel Oncology Ltd Pharmaceutical compounds
CN107635984B (en) 2015-03-11 2021-04-13 Fmc公司 Heterocyclic substituted bicyclic azoles as pesticidal agents
GB201506933D0 (en) 2015-04-23 2015-06-10 Sentinel Oncology Ltd Pharmaceutical compounds
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
MA43072A (en) 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
TW201718546A (en) 2015-10-02 2017-06-01 英塞特公司 Heterocyclic compounds useful as PIM kinase inhibitors
KR20180081520A (en) 2015-11-12 2018-07-16 에프. 호프만-라 로슈 아게 Compounds for the Treatment of Amyotrophic Lateral Sclerosis
CN108289959B (en) 2015-11-12 2021-07-16 豪夫迈·罗氏有限公司 Composition for treating spinal muscular atrophy
US10383867B2 (en) 2015-11-28 2019-08-20 Russell Dahl Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders
CN108697709A (en) * 2015-12-10 2018-10-23 Ptc医疗公司 Method for treating Huntington disease
JP6872550B2 (en) 2015-12-10 2021-05-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Crosslinked piperidine derivative
US10526345B2 (en) 2016-04-08 2020-01-07 Mankind Pharma Ltd. Compounds as GPR119 agonists
AR108325A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
MA45270A (en) 2016-05-04 2017-11-09 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
WO2017210134A1 (en) * 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
US20190264267A1 (en) 2016-07-25 2019-08-29 Wave Life Sciences Ltd. Phasing
TW201819386A (en) 2016-10-24 2018-06-01 美商傳達治療有限公司 SHP2 phosphatase inhibitors and methods of use thereof
US11857599B2 (en) 2017-04-03 2024-01-02 Acceleron Pharma Inc. Compositions and methods for treating spinal muscular atrophy
EP3630770A1 (en) 2017-05-26 2020-04-08 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
WO2018226622A1 (en) 2017-06-05 2018-12-13 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
EP3644996B1 (en) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Methods for treating huntington's disease
SG11202000980QA (en) 2017-08-04 2020-02-27 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
WO2019165073A1 (en) 2018-02-21 2019-08-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
RU2020134302A (en) 2018-03-21 2022-04-22 Рилэй Терапьютикс, Инк. SHP2 PHOSPHATASE INHIBITORS AND METHODS OF THEIR APPLICATION
EP3768680A1 (en) 2018-03-21 2021-01-27 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
CN112135815A (en) 2018-03-27 2020-12-25 Ptc医疗公司 Compounds for the treatment of huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CA3103976A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
CN113840602A (en) 2019-03-15 2021-12-24 斯基霍克疗法公司 Compositions and methods for correcting aberrant splicing
WO2020231977A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
TW202131920A (en) 2019-11-01 2021-09-01 瑞士商諾華公司 The use of a splicing modulator for a treatment slowing progression of huntington’s disease
JP2023522177A (en) 2020-04-09 2023-05-29 ピーティーシー セラピューティクス， インコーポレイテッド Compounds for treating Huntington's disease
US20220162610A1 (en) 2020-11-12 2022-05-26 Ptc Therapeutics, Inc. Novel rna transcript
EP4377317A1 (en) 2021-07-30 2024-06-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease

Also Published As

Publication number Publication date
US20210238186A1 (en) 2021-08-05
AU2023203241A1 (en) 2023-06-15
PE20211378A1 (en) 2021-07-27
US11858941B2 (en) 2024-01-02
CL2021003022A1 (en) 2022-07-01
KR20210042265A (en) 2021-04-19
EP3814357A1 (en) 2021-05-05
WO2020005873A1 (en) 2020-01-02
AU2019294478B2 (en) 2023-03-23
CN112654625A (en) 2021-04-13
IL279688A (en) 2021-03-01
CL2020003378A1 (en) 2021-06-18
JP7421507B2 (en) 2024-01-24
JP2021528467A (en) 2021-10-21
EP3814357B1 (en) 2024-05-01
CL2022003434A1 (en) 2023-06-02
MX2020014098A (en) 2021-05-27
BR112020026545A2 (en) 2021-03-23
AR119651A1 (en) 2022-01-05
CO2020016285A2 (en) 2021-01-18
EA202092896A1 (en) 2021-04-13
CA3103976A1 (en) 2020-01-02
AU2019294478A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
IL279688A (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
IL279714A (en) Heteroaryl compounds for treating huntington's disease
IL277497A (en) Compounds for treating huntington's disease
IL271046A (en) Compounds for treating huntington's disease
EP3644996A4 (en) Methods for treating huntington's disease
IL287945A (en) Compounds for treating huntington's disease
EP3645121A4 (en) Methods for treating huntington's disease
IL281633A (en) Methods for treating huntington's disease
IL277182A (en) Compositions and methods for treating parkinson's disease
IL290770A (en) Compounds and methods for treating oxalate-related diseases
EP3398614A4 (en) Agent for preventing and/or treating alzheimer's disease
EP3746057A4 (en) Method for preventing or treating alzheimer's disease
PL3285755T3 (en) Creatine hydrochloride for the treatment of huntington's disease
EP3429569A4 (en) Methods for preventing or treating parkinson's disease by the farnesylation of paris
EP3570841A4 (en) PPARy AGONIST FOR THE TREATMENT OF HUNTINGTON'S DISEASE
SG11202101274XA (en) Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease
EP3843724A4 (en) Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease
ZA202107235B (en) Compositions and methods for treating ocular disease
ZA202007616B (en) Pharmaceutical composition for preventing or treating aids comprising rhodanine derivative
IL282700A (en) Heterocyclic compounds for the treatment of epilepsy
SG11202109180RA (en) Compositions and methods for treating huntington's disease
EP3807254A4 (en) Heterocyclic compounds useful in the treatment of disease
SG11202005278PA (en) Compounds for treating eye diseases and methods thereof
EP3607949A4 (en) Composition for preventing and treating muscular disease
GB201808464D0 (en) Pharmaceutical compounds for use in treating huntington's disease